Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Paramount Has Offered $15 Million to Settle CBS Lawsuit. Trump Wants More. The president's team threatened another lawsuit amid settlement talks. The AI chip maker's shares rose more than 5% after ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...